Abstract Mitochondria are critical for cellular energetic metabolism, intracellular signaling orchestration and programmed death regulation. Therefore, mitochondrial dysfunction is associated with various pathogeneses. The maintenance of mitochondrial homeostasis and functional recovery after injury are coordinated by mitochondrial biogenesis, dynamics and autophagy, which are collectively referred to as mitochondrial quality control (MQC). There is increasing evidence that mitochondria are important targets for melatonin to exert protective effects under pathological conditions. Melatonin, an evolutionarily conserved tryptophan metabolite, can be synthesized, transported and metabolized in mitochondria. In this review, we summarize the important role of melatonin in the elimination of damaged mitochondria and the recovery of mitochondrial energy supply by regulating MQC, providing new strategies for clinical treatment of mitochondria-related diseases.
Introduction
Mitochondria serve as the metabolic hubs of the cell, yet they are also the primary sites of oxidative damage. When these organelles fail, the resulting dysfunction becomes a hallmark of aging, cancer, neurodegeneration, and cardiovascular disease. To maintain cellular health, organisms rely on Mitochondrial Quality Control (MQC)—a tripartite system encompassing biogenesis (the creation of new mitochondria), dynamics (the balance of fission and fusion), and mitophagy (the recycling of damaged components).
While melatonin is widely recognized as a "sleep hormone" and a potent antioxidant, emerging evidence suggests it acts as a sophisticated master regulator of the MQC machinery. This review synthesizes recent research to map the biochemical pathways through which melatonin intervenes in mitochondrial life cycles, offering a roadmap for potential clinical therapies.
The Mitochondrial Melatonin Factory and Metabolic Regulation
A defining characteristic of melatonin is its localized action. Unlike many hormones that act on distant targets, melatonin is synthesized, transported, and metabolized directly within the mitochondria. This suggests it evolved as an immediate "first responder" to mitochondrial stress. Research indicates that the concentration of melatonin in mitochondria can be up to 100 times higher than in blood plasma, underscoring its specialized role.
Beyond its role as a scavenger of reactive oxygen species (ROS), melatonin facilitates metabolic reprogramming. In certain pathological states, such as cancer, melatonin can drive a metabolic switch from cytosolic glycolysis back to mitochondrial oxidative phosphorylation (OXPHOS). It achieves this by regulating acetyl-CoA levels and influencing the activity of the pyruvate dehydrogenase complex (PDHC) via PDK4 inhibition.
Orchestrating Mitochondrial Dynamics
Mitochondrial health depends on a delicate balance between fusion (merging) and fission (splitting). Damaged mitochondria often undergo excessive fission, leading to fragmentation and cell death. Melatonin acts as a stabilizer in this process, inhibiting fission-related proteins like Drp1 and Fis1 while promoting fusion-related proteins such as Mfn1/2 and Opa1.
For instance, in models of myocardial ischemia/reperfusion injury, melatonin has been shown to stabilize the Opa1 protein via the Yap-Hippo pathway. By regulating signaling axes like AMPK and SIRT3, melatonin allows mitochondria to share resources and recover from injury rather than breaking apart.
Antioxidant Defense and Bidirectional Autophagy
Melatonin enhances the cell's endogenous antioxidant defenses by increasing the activity of enzymes like superoxide dismutase (MnSOD) and glutathione peroxidase (GSH-Px). Furthermore, it directly boosts ATP production by enhancing the activities of mitochondrial Complexes I and IV, which is critical for recovery in brain and liver injury models.
One of the most nuanced roles of melatonin is its "Goldilocks" approach to autophagy. Depending on the pathological context, melatonin can either promote mitophagy to clear damaged organelles or inhibit it if the process becomes excessive and threatens cell survival. This bidirectional regulation ensures that mitochondrial recycling remains within a homeostatic range.
Future Perspectives and Limitations
Despite the promising findings in cell cultures and animal models, several hurdles remain for clinical translation. Most current evidence is derived from preclinical studies, and large-scale human clinical trials are necessary to validate melatonin as a therapeutic for MQC-related diseases. Additionally, further research is needed to understand the context-specific mechanisms that dictate melatonin's influence on autophagy and its long-term safety profile when used specifically for mitochondrial modulation rather than sleep regulation.
Summary updated